Skip to main content

An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia



Human papillomavirus (HPV) is a common sexually transmitted infection and the leading cause of cervical cancer. The HPV vaccine is a safe and effective way to prevent HPV infection. In Zambia, the vaccine is given during Child Health Week to girls aged 14 years who are in and out of school in two doses over two years. The focus of this evaluation was to establish the cost to administer a single dose of the vaccine as well as for full immunisation of two doses.


This work was part of a broader study on assessing HPV programme implementation in Zambia. For HPV costing aspect of the study, with a healthcare provider perspective and reference year of 2020, both top-down and micro-costing approaches were used for financial costing, depending on the cost data source, and economic costs were gathered as secondary data from Expanded Programme for Immunisation Costing and Financing Project (EPIC), except human resource costs which were gathered as primary data using existing Ministry of Health salary scales and reported time spent by different health cadres on activities related to HPV vaccination. Data was collected from eight districts in four provinces, mainly using a structured questionnaire, document reviews and key informant interviews with staff at national, provincial, district and health facility levels. Administrative coverage rates were obtained for each district.


Findings show that schools made up 53.3% of vaccination sites, community outreach sites 30.9% and finally health facilities 15.8%. In terms of coverage for 2020, for the eight districts sampled, schools had the highest coverage at 96.0%. Community outreach sites were at 6.0% of the coverage and health facilities accounted for only 1.0% of the coverage. School based delivery had the lowest economic cost at USD13.2 per dose and USD 28.1 per fully immunised child (FIC). Overall financial costs for school based delivery were US$6.0 per dose and US$12.4 per FIC. Overall economic costs taking all delivery models into account were US$23.0 per dose and US$47.6 per FIC. The main financial cost drivers were microplanning, supplies, service delivery/outreach and vaccine co-financing; while the main economic cost drivers were human resources, building overhead and vehicles. Nurses, environmental health technicians and community-based volunteers spent the most time on HPV related vaccination activities compared to other cadres and represented the greatest human resource costs.


The financial cost of HPV vaccination in Zambia aligns favourably with similar studies conducted in other countries. However, the economic costs appear significantly higher than those observed in most international studies. This discrepancy underscores the substantial strain placed on healthcare resources by the program, a burden that often remains obscured. While the vaccine costs are currently subsidized through the generous support of Gavi, the Vaccine Alliance, it’s crucial to recognize that these expenses pose a considerable threat to long-term sustainability. Consequently, countries such as Zambia must proactively devise strategies to address this challenge.

Peer Review reports


Human papillomavirus (HPV) is a common sexually transmitted infection that can cause a range of health problems, including genital warts and certain types of cancer [1,2,3]. The HPV vaccine is a safe and effective way to prevent HPV infection and the health problems it can cause [1, 2, 4].

Since 2019, the HPV vaccine in Zambia is provided through the country’s Expanded Programme on Immunisation (EPI), once a year during the Child Health Week (CHW) in the month of June, targeting girls aged 14 years who are in and out of school. The overall target for the programme is girls aged 9 to 14, but so far only the 14-year-olds have been vaccinated owing to inadequate doses of HPV vaccine being available on the global market and thus Gavi could only secure a limited number of vaccines [5,6,7].

The Zambian EPI prioritized the vaccination of 14-year-olds, as it represented their final opportunity to receive the vaccine before surpassing the age limit. HPV vaccine distribution in Zambia employs various channels, including health facilities, schools, and community outreach sites, to ensure widespread accessibility and uptake. The primary focus of social mobilization and messaging revolves around maximizing vaccination rates among schoolgirls, with health facilities and outreach sites catering to those not enrolled in school. The Ministry of Health collaborates with international and non-governmental partners to facilitate vaccine accessibility, promote public awareness of vaccination’s significance, and dispel vaccine-related myths and misconceptions.

Gavi, the Vaccine Alliance, played a vital role in supporting HPV vaccine delivery by providing funding to the country’s national immunization program to help cover the costs of purchasing and distributing the vaccine [5]. Gavi has also provided technical assistance and capacity building to help the Ministry of Health implement effective strategies for increasing vaccine uptake, and has supported the training of health care workers to administer the vaccine safely and effectively.

In recommending HPV vaccine introduction the Zambia Immunisation Technical Advisory Group, ZITAG, used cost and cost-effectiveness studies from Brazil, Canada, the United Kingdom, and Tanzania [6, 8]. The transferability of such findings to the Zambian context was arguable and such decisions were often heavily influenced by global level directives made by donors (Wilkinson, Sculpher et al. 2016) [6].

A PATH study during the demonstration project estimated the financial cost at between US$9.98 and US$10.40 per fully immunised girl (PATH 2014) [9]. A Gavi Full Country Evaluation (FCE) report stated that the financial and programmatic sustainability implications of introducing HPV vaccine nationally were not thoroughly assessed using local evidence and recommended that the Ministry of Health develop clear policy and guidelines for purposes of economic evaluation of new vaccine introductions [6]. As Zambia proceeds with the national introduction the question is now centred around understanding the cost of vaccination for a nationwide programme compared to a demonstration project in only one province. The objective of this paper was to establish the cost to administer as single dose as well as to get a girl fully vaccinated across the three delivery platforms being utilised, namely school, community outreach and health facility, now that HPV vaccination is nationwide. The paper also highlights an approach that can be taken to apportion costs across different vaccine delivery platforms in settings where such apportionment may be challenging.


For HPV costing, a healthcare provider perspective was used and both top-down and micro-costing approaches were exploited, depending on the source of the cost data, to estimate the financial and economic costs of implementing HPV vaccination using the delivery model of child health week [10]. Primary data was collected for financial costing as well as the economic cost of human resources, and secondary data from the updated Expanded Programme for Immunisation Costing and Financing Project (EPIC) study was used for the other economic costs [11]. Primary data was collected between July and September 2020. The EPIC study is a comprehensive study aimed at assessing routine immunization and new vaccines costs with a view to optimizing the costs and financial sustainability of immunization programs worldwide, and it included Zambia as one of its focus countries [11]. Micro-costing is a method of estimating the costs of delivering a specific intervention or program at a detailed level and involves identifying and quantifying all of the resources and activities that are needed to deliver the intervention or program, and then assigning a cost to each of these elements. Top-down costing is a high-level approach that estimates the overall cost of a program or service based on aggregated data and in this case, this was data from national level budgets of the Expanded Programme on Immunisation. Table 1 summarises the resource input categories. Some primary data was gathered from 2019 and others from 2020 vaccination week and the 2019 costs were inflated to 2020 equivalent at 9.15% inflation rate [12]. Costs were gathered in both USD and ZMW and exchange rate of ZMW18.36 was used for 2020, based on Bank of Zambia exchange rate data [13].

Table 1 Micro-costing for HPV vaccination in Zambia – Resource Input Categories

Data for these costs was collected at both national and subnational levels mainly using a structured questionnaire, supplemented by document reviews (HPV microplans, reports, budgets) and key informant interviews with staff at national, provincial, district and health facility levels. A sample of eight districts in four provinces was included in order to be more representative than the earlier demonstration phase costing. The sample for the subnational level built on the EPI Costing and Financing Project (EPIC) sample with inclusion of an additional province in consultation with the Ministry of Health [14]. These were Lusaka province (Lusaka and Chongwe districts); Copperbelt province (Ndola and Lufwanyama districts); Central province (Kabwe and Mkushi districts) and Muchinga province as the addition (Mpika and Chinsali districts). Expenditure data on all key activities, including planning, social mobilization, vaccines and other supplies, service delivery, supervision, data collection and compilation, was included. In addition, the data collection tool included information on number of health facilities, outreach sites as well as schools that were utilised in the HPV vaccination exercise, as well as coverage data across all these sites for each district sampled. For all these costs there was specific emphasis on where the costs were incurred with reference to the delivery models of school, community outreach and health facility.

Data analysis varied according to data source and level of data. For national level data, costs were allocated to each district if they were budgeted as such as the budget matched the expenditure as illustrated by relevant personnel providing the data. Costs that were not specific to a district were allocated by dividing the total cost by the number of districts in the country. For data collected from the eight sampled districts, total costs for all eight districts and average costs per district were calculated. The total costs were apportioned to each delivery model (school, health facility and outreach) based on the proportion of vaccination sites utilised for each model. This approach was used as it was generally not possible to allocate specific costs to each delivery model due to the manner in which district level budgets were made without such specific reference to each delivery model. Economic costs were gathered from EPIC study data. Univariate and multivariate sensitivity analysis was carried out to assess the output with cost per dose as the dependent variable and all cost inputs listed in Table 2 as independent variables, adjusting them between 1 and 10% [15,16,17].

Table 2 Costs attributable to HPV Vaccination in Zambia, 2020

The total costs was apportioned to each delivery model based on the data in Table 3 on the proportion of delivery sites for each model. This was divided by the coverage (dose 1 and dose 2) for each model as outlined in Table 4 to arrive at the cost per dose. For overall costs and across delivery models, the cost per fully immunised child was arrived at by dividing total costs by number of fully immunised girls for each delivery models.


Table 3 provides details of the three delivery models used in Zambia for HPV vaccine delivery across the eight sampled districts. Schools made up more than half the sites for vaccination, followed by community outreach sites and finally health facilities. This was used as a basis for apportioning costs later.

Table 3 HPV Delivery models in Zambia

In terms of coverage for 2020, for the eight districts sampled, schools had the highest coverage, averaging 93% of the coverage across first and second doses. Community outreach sites were at 6.0% of the coverage and health facilities accounted for only 1.0% of the coverage as shown in Table 3.

Table 4 gives details of the costs attributable to HPV vaccination in Zambia. The table shows that schools represented the major high number of administered doses for both first and second doses, followed by outreach sites and finally health facilities had vaccine doses adminsitered. Second dose (full immunisation) accounted for 46.3% of all doses administered in the sampled districts in 2020.

Table 4 HPV Vaccine Doses administered 2020

As illustrated in Table 2, human resource-related costs remain the largest costs associated with the EPI programme and HPV vaccination is no exception. In the table above, most of the costs, other than vaccine costs, related to staff allowances, per diem and fuel (microplanning, training, service delivery and outreach). Enrolled Nurse/Midwife position accounted the largest proportion of time spent on HPV vaccination by all cadres at 27.4%. This was followed by Registered Nurse/Midwife at 24.7%, Environmental Health Technologist (EHT) at 12.2%, Community based volunteers (CBV) at 11.2% and clinical officers at 6.6%. Social mobilisation and supervision/monitoring and evaluation were highly underfunded, according to key informants who stated that it was inadequate.

Finally, Table 5 provides the calculated costs based on the foregoing tables. School based delivery had the lowest cost economic cost at USD13.2 per dose and USD 28.1 per fully immunised child. It also had the lowest financial cost at US$3.4 per dose and US$7.3 per FIC. Total financial costs across all delivery platforms were US$6.0 per dose and US$12.4 per fully immunised child. Overall economic costs taking all delivery models into account were US$23.0 per dose and US$47.6 per FIC.

Table 5 HPV vaccinations cost per dose and perf fully immunised child in Zambia

Sensitivity analysis showed that health facility delivery is most affected by changes in costs, mainly due to the low coverage achieved there. Schools were least sensitive to changes in costs due to higher coverage.


The cost of administering HPV vaccine across different delivery platforms in Africa is a critical factor in determining the success of HPV vaccination programs [17,18,19,20,21]. School-based delivery has been shown to be the most economical method for delivering the vaccine, as it requires minimal resources when we consider the cost per FIC, and it can be implemented quickly with higher coverage in most countries [18, 20, 22, 23]. The findings of this evaluation support this as school based HPV vaccine delivery had the highest coverage and lowest cost per dose. According to key informants, orientation and social mobilisation efforts were highly focused on the schools and less so on health facility access and outreach. This may disadvantage out-of-school girls in terms of accessing the vaccine [18]. Additionally, personnel based at health facilities were not so focused on HPV vaccination, despite them being mandated to do so. Both health facility and community outreach were meant to help with vaccinating out-of-school girls, a hard-to-reach population [18]. In Cambodia and Zimbabwe, out-of-school girls identified by community health workers were invited to come to schools for vaccination, But the effectiveness of this approach could not be shown, illustrating the enormity of the challenge [20, 24].

Health facility-based delivery is also potentially an efficient option, although the cost of facility-based delivery is higher due to the need for additional equipment and personnel and usually lower coverage in most countries that have implemented this approach [18, 20]. Community-based delivery is an important option for reaching rural and hard-to-reach populations, but the cost of community-based delivery is often higher than school-based or health facility-based delivery due to logistical challenges, higher economic costs, and the need for additional resources to do with social mobilisation, for example [20]. Cost-effectiveness studies have shown that the cost of delivering the HPV vaccine through different delivery platforms in Africa can vary significantly, depending on the type of delivery platform, the population being targeted, and the resources available [18].

A study of costs of HPV vaccination in Gavi supported countries using the World Health Organization Cervical Cancer Prevention and Control Costing Tool found the average economic cost per dose to have been US$19.98, and US$8.74 as the financial cost across one year demonstration projects [17]. The economic cost of US$23.0 per dose for Zambia from this study is compared to other available studies in the African countries [18,19,20,21,22,23,24]. In these studies, the highest economic cost per dose at US$45.0 was in Zimbabwe and the lowest at US$3.09 was in Mwanza district in Tanzania, although the national average of US$10.62 for Tanzania may be a better comparison. Senegal had an economic cost of US$12.24 and financial cost of US$ 7.75, whereas Mozambique had an economic cost of US$24 [25].

In terms of financial costs the main cost drivers in Zambia were supplies (e.g. syringes, needles, safety boxes etc.) as well as costs associated with per diems and allowances for staff and community workers and volunteers (relating to microplanning, training, orientation, social mobilisation and monitoring and evaluation as well as actually vaccination activities). When we consider economic costs human resource costs were the largest, followed by buildings and vehicles and then cold chain equipment and maintenance.

Human resource related costs in terms of per diems, allowances and salaries were the largest cost drivers for most of the countries whose studies have been included here [18,19,20,21,22,23,24]. As shown in the results, nurses (both enrolled and registered) made up over half of the total time spent by all cadres on HPV immunisation activities, with the next most utilised cadres being CBVs. The EHTS took up roles related to social mobilisation and community outreach due to lack of specific cadres employed for such work. M&E Officer, Accountant, driver and community health assistants were additional positions that dedicated the most time ranging between 2% and 3.5%. Planning for HPV vaccination in Zambia thus needs to prioritise these critical positions in terms or resource allocation and support.

Demonstration project data for Gavi supported countries showed that social mobilisation and service delivery were the largest cost drivers, but this did not take into account economic costs [18]. However, this is not usually the case beyond demonstration projects as social mobilisation was usually heavily funded for demonstration projects but not as well funded during the actual national implementation, as have been the case in Zambia. In fact when funds are limited, activities like social mobilisation become the likely victims of reduced allocation of funds. Monitoring and evaluation is another area that is often under-funded during national rollout when funds are more limited.

One of the main drivers of cost for HPV vaccination in Africa is the cost of the vaccine itself. However, many Gavi supported countries do not bear the entire vaccine cost. Gavi, has negotiated vaccine prices with manufacturers and accessed the bivalent vaccine at US$4.50 and the quadrivalent vaccine at US$4.60 per dose [17]. In Zambia, the government only put up US$0.55 per dose as their co-finance contribution to the Gavi support. Without Gavi support, vaccine costs become a major cost driver and barrier to HPV vaccination programmes in Africa. Strategies thus need to be put in place in countries like Zambia to cater for how the vaccine cost will be funded once Gavi support ceases.

There are several methodological challenges and complexities associated with apportioning costs across HPV Vaccination delivery platforms which form part of the limitations of this study [26, 27]. Data availability and quality is one such challenge as obtaining accurate and detailed cost data can be challenging, particularly in low-resource settings where financial and administrative systems may be less developed. Incomplete or missing data can lead to inaccurate cost estimates [27, 28]. In this study, for example, supporting documents for financial data provided were not always available there was also some likelihood of recall bias given time from activity to this data collection. Secondly, allocating costs for shared resources, such as personnel, facilities, and equipment, can be complex. Different methods, such as direct allocation or step-down allocation, may produce varying results, and the choice of method can significantly impact cost estimates [26, 28]. This study settled on using EPIC data for most of the economic costs, other than human resources.

Thirdly, The costs of delivering the HPV vaccine may vary depending on factors such as geography, population density, and infrastructure. This variability can make it challenging to generalize cost estimates across different delivery platforms and settings. Lastly, the costs of HPV vaccination programs can change over time as the program scales up, achieves economies of scale, or faces changes in vaccine prices as well as fluctuations in exchange rates [29]. Accounting for these changes in cost estimates is crucial for accurately assessing the cost-effectiveness of the program [30, 31].

The problem of cost allocation across delivery platforms if further compounded by having multiple sources of funds, including government monthly grants and special funding from donors such as Gavi, and Unite Nations agencies which may not be earmarked for any one particular delivery platform.


The financial cost of HPV vaccination in Zambia aligns favourably with similar studies conducted in other countries. However, the economic costs appear significantly higher than those observed in most international studies. This discrepancy underscores the substantial strain placed on healthcare resources by the program, a burden that often remains obscured. While the vaccine costs are currently subsidized through the generous support of Gavi, the Vaccine Alliance, it’s crucial to recognize that these expenses pose a considerable threat to long-term sustainability. Consequently, countries such as Zambia must proactively devise strategies to address this challenge.

Data availability

Data is available on request from the corresponding author.



Community–based volunteer


Child Health Week


Environmental Health Technologist


Expanded Programme on Immunisation


Expanded Programme for Immunisation Costing and Financing Project


Full Country Evaluation


Fully Immunised Child


Human Papilloma Virus


Monitoring and Evaluation


Ministry of Health


Zambia Immunisation Technical Advisory Group


  1. Gupta G, Glueck R, Patel PR. HPV vaccines: global perspectives. Hum Vaccin Immunother. 2017;13(6):1–4.

    Article  PubMed  Google Scholar 

  2. Prue G, Lawler M, Baker P, Warnakulasuriya S. Human papillomavirus (HPV): making the case for ‘Immunisation for all’. Oral Dis. 2017;23(6):726–30.

    Article  CAS  PubMed  Google Scholar 

  3. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D et al. Human Papillomavirus and Related Diseases in Zambia. Summary Report 27 July 2017. 2017.

  4. Audisio RA, Icardi G, Isidori AM, Liverani CA, Lombardi A, Mariani L, et al. Public health value of universal HPV vaccination. Crit Rev Oncol Hematol. 2016;97:157–67.

    Article  PubMed  Google Scholar 

  5. Gavi. (2017). Gavi IRC Report on HPV in Zambia, Nov 2017.

  6. Gavi. (2018) First Report of the Gavi Full Country Evaluations Phase 2, Zambia. Gavi; 2018.

  7. WHO. WHO HPV Vaccine Global Market Study, April 2022. World Health Organsiation; 2022.

  8. ZITAG. Minutes of the ZITAG Ad hoc Meeting fo 4th September 2017. 2017.

  9. PATH. Estimated costs of introduction of human papillomavirus vaccine in Zambia. PATH; 2014.

  10. Vassall A, et al. Reference case for estimating the costs. of Global Health Services and Interventions.; 2018.

  11. Schutte C, et al. Cost Anal Routine Immun Zambia Vaccine. 2015;33(Suppl 1):A47–52.

    Google Scholar 

  12. World Bank. Inflation, consumer prices (annual %) - Zambia available at:

  13. Bank of Zambia. Monetary And Financial Statistics. Available at:

  14. Schütte C, Kinghorn A, Chansa C, Marinda E, Guthrie T, Banda S et al. Technical Report - Costing and Financing Analyses of Routine Immunization in Zambia. Johannesburg: Health and Development Africa; 2014.

  15. Thinkwell. Immunization delivery cost catalogue (IDCC) codebook & definitions. Thinkwell Global; 2020.

  16. Thinkwell. Estimating the cost of the integrated MR campaign in Sierra Leone. Thinkwell Global; 2021.

  17. Thinkwell. How to cost an immunization campaign? Thinkwell Global; 2021.

  18. Botwright S, Holroyd T, Nanda S, Bloem P, Griffiths UK, Sidibe A, et al. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects. PLoS ONE. 2017;12(10):e0182663.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Brennan T, Hidle A, Doshi RH, An Q, Loharikar A, Casey R, et al. Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal. Vaccine. 2022;40(Suppl 1):A77–84.

    Article  PubMed  Google Scholar 

  20. Hidle A, Gwati G, Abimbola T, Pallas SW, Hyde T, Petu A, et al. Cost of a human papillomavirus vaccination project, Zimbabwe. Bull World Health Organ. 2018;96(12):834–42.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, et al. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. BMC Med. 2012;10:136.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Levin A, Wang SA, Levin C, Tsu V, Hutubessy R. Costs of introducing and delivering HPV vaccines in low and lower middle-income countries: inputs for GAVI policy on introduction grant support to countries. PLoS ONE. 2014;9(6):e101114.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Quentin W, Terris-Prestholt F, Changalucha J, Soteli S, Edmunds WJ, Hutubessy R, et al. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC Med. 2012;10:137.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Garon J, Wuddhika IV, Sreenivasan N, Wannemuehler K, Vutthikol Y, Chhorvann C, et al. Community-based household assessment of human papillomavirus (HPV) vaccination coverage and acceptability - HPV vaccine demonstration program. Cambodia – 2017 Vaccine. 2019;37(9):1202–8.

    PubMed  Google Scholar 

  25. Soi C, Babigumira JB, Chilundo B, Muchanga V, Matsinhe L, Gimbel S, et al. Implementation strategy and cost of Mozambique’s HPV vaccine demonstration project. BMC Public Health. 2019;19(1):1406.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Vaughan K, Ozaltin A, Mallow M, Moi F, Wilkason C, Stone J, Brenzel L. The costs of delivering vaccines in low- and middle-income countries: findings from a systematic review. Vaccine X. 2019;2:100034. PMID: 31428741; PMCID: PMC6697256.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Akumbom AM, Lee JJ, Reynolds NR, Thayer W, Wang J, Slade E. Cost and effectiveness of HPV vaccine delivery strategies: a systematic review. Prev Med Rep. 2022;26:101734. PMID: 35251910; PMCID: PMC8889236.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003;1(1):8. PMID: 14687420; PMCID: PMC320499.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Conteh L, Walker D. Cost and unit cost calculations using step-down accounting. Health Policy Plan. 2004;19(2):127–35. PMID: 14982891.

  30. Levin CE, Van Minh. Hoang, Odaga, John, Rout, Swampa Sarit, Ngoc, Diep Nguyen Thi. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bulletin of the World Health Organization. 2013;91(8):585–92. World Health Organization.

  31. Hutton G, Baltussen R. Cost valuation in resource-poor settings. Health Policy Plan. 2005;20(4):252-9. PMID: 15965037.

Download references


The authors acknowledge the support and assistance of the Ministry of Health, the Permanent Secretary (Technical Services) Dr. Kennedy Malama, Dr. Andrew Silumesii (Director Public Health and Research), Mr. Henry Kansembe (Director Policy and Planning), Dr. Bobo (Deputy Director Public Health and Research), Mr. Patrick Banda (Deputy Director Planning and Budgeting), Dr. Francis Dien Mwansa (Country EPI Manager) and the entire staff at the Child Health Unit. Our team also acknowledges the invaluable time and support received from health workers and community health volunteers in all the provinces and districts where we conducted our field research. We also thank several individuals representing a broad spectrum of EPI institutional partners in Zambia who participated in this study. Special thanks also go to the Steering Committee for the evaluation. We are grateful to the Gavi Evaluation team led by Esther Saville we also thank Ms. Billie Nieuwenhuys, the Senior Country Manager for Zambia, for her support during the course of this evaluation. While we remain greatly indebted to the support and contributions to this evaluation of all the individuals and institutions mentioned, the responsibility for any errors of fact or interpretation remain entirely with us.


Research funding and trainee support for the first author was provided by the UNC-UNZA-Wits Partnership for HIV and Women’s Reproductive Health which is funded by the U.S. National Institutes of Health (grant number D43 TW010558). Additional funding for data collection provided by the Gavi Evaluation of Immunisation Sustainability Project under the University of Zambia School of Humanities and Social Sciences, Department of Economics.

Author information

Authors and Affiliations



Moses C Simuyemba – Research design, data collection, data cleaning and analysis, first author on manuscript.Chitalu M Chama - Chiliba - Research design, data collection, second author on manuscript.Abson Chompola - Research design, data collection, authorship of articleAaaron Sinyangwe - Research design, data collection, authorship of articleAbdallah Bchir - Research advisor and reviewer on paperGilbert Asiimwe - Research advisor and reviewer on paperCarla Chibwesha – PhD supervisor involved at all stages of the work Felix Masiye - Research design, data collection, data analysis, authorship of article, PI on researchAll authors reviewed the mansucript.

Corresponding author

Correspondence to Moses C Simuyemba.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Ethics approval was obtained from the University of Zambia Humanities and Social Sciences Research Ethics Committee (Clearance number HSSREC 2020-Mar 004a). Further approval was obtained from the National Health Research Authority (NHRA) as well as administrative approval from the Zambia Ministry of Health (MOH). Study methodology and all tools, including key informant interview guides and data extraction tools were reviewed by the ethics board, NHRA and MOH. Informed consent was obtained from all the participants. All methods were carried out in accordance with relevant guidelines and regulations of the ethics board and NHRA.

Consent for publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Supplementary Material 3

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Simuyemba, M.C., Chama-Chiliba, C.M., Chompolola, A. et al. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia. BMC Infect Dis 24, 369 (2024).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: